KNSA

Kiniksa Pharmaceuticals Ltd.

Price

$75.61

return (12m)

96.44%

p/e

72.72

p/bv

8.97

DIVIDEND YIELD

0.00%

KNSA price

Kiniksa Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment KNSA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-4.57%

3 months

18.41%

1 year

96.44%

2 years

211.28%

5 years

593.03%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals KNSA

Valuation

P/E

72.72

Sector -3.46

Industry -3.46

P/BV

8.97

Sector 1.94

Industry 1.94

P/Revenue (PSR)

6.98

Sector 1.96

Industry 1.96

EV/EBITDA

193.01

Sector -216.42

Industry -216.42

EV/EBIT

196.36

Sector -46.11

Industry -46.11

P/EBITDA

57.48

Sector -21.02

Industry -21.02

P/EBIT

58.51

Sector -27.60

Industry -27.60

P/Total Assets

6.55

Sector 1.14

Industry 1.14

P/Net Current Assets

13.75

Sector -10.24

Industry -10.24

P/Working Capital

11.79

Sector -162.19

Industry -162.19

EPS

1.04

Sector -1.78

Industry -1.78

BVPS

8.43

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

89.82%

Sector 41.35%

Industry 41.35%

EBITDA Margin

11.36%

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

11.16%

Sector -4,203,320.32%

Industry -4,203,320.32%

Operating Margin

11.92%

Sector -35.47%

Industry -35.47%

Net Profit Margins

9.59%

Sector -35.90%

Industry -35.90%

Asset Turnover

0.27

Sector 0.03

Industry 0.03

Profitability

ROE

12.33%

Sector -57.40%

Industry -57.40%

ROA

9.00%

Sector -59.43%

Industry -59.43%

ROIC

32.83%

Sector -2,370.21%

Industry -2,370.21%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

3.90

Sector 2.91

Industry 2.91

Net Debt / EBITDA

-19.01

Sector -21.98

Industry -21.98

Net Debt / EBIT

-19.34

Sector -8.44

Industry -8.44

Net Debt / Equity

-0.80

Sector -33,112.99

Industry -33,112.99

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.73

Sector 0.46

Industry 0.46

Liabilities/Assets

0.27

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

85.24%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals KNSA

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Kiniksa Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$75.61

Fair Value

$14.04

Upside

-81.42%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
KNSA Kiniksa Pharmaceuticals Ltd.	$75.61	95.68%	0.00%	72.72	8.97	12.33%	9.59%
PFE Pfizer Inc.	$27.48	8.11%	6.26%	36.14	1.83	5.07%	6.80%
ABBV AbbVie Inc.	$259.97	9.77%	2.63%	72.88	-77.57	-106.44%	9.81%
NVO Novo Nordisk A/S	$37.23	-33.47%	4.98%	9.10	4.83	53.11%	35.32%
MRK Merck & Co. Inc.	$143.18	65.09%	2.36%	110.80	8.37	7.56%	4.77%
AZN AstraZeneca PLC	$156.59	-4.79%	2.06%	18.71	4.82	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$60.33	34.59%	4.20%	13.14	5.46	41.59%	18.87%
ZTS Zoetis Inc.	$69.46	-51.82%	3.01%	11.00	9.21	83.77%	27.69%
AMGN Amgen Inc.	$402.15	38.44%	2.47%	24.84	18.58	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$729.88	22.13%	0.51%	17.33	2.37	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$108.98	45.42%	0.00%	30.90	89.03	288.13%	24.86%
MCK McKesson Corporation	$888.29	16.56%	0.38%	22.96	-27.29	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$501.27	24.01%	0.00%	28.87	6.28	21.76%	35.00%
CAH Cardinal Health Inc.	$226.17	45.05%	0.91%	30.94	-19.47	-62.92%	0.67%
ARGX argenx SE	$914.13	19.13%	0.00%	20.47	5.36	26.20%	25.70%
HRMY Harmony Biosciences Holdings Inc.	$39.41	46.40%	0.00%	12.60	2.28	18.14%	18.88%
BIIB Biogen Inc.	$220.34	42.87%	0.00%	38.99	1.73	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

KNSA - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Ltd.

Average Investor10 user rating

4.0 (5 people)

United States

11 years

Founded: 2015

2018

Time since IPO - 8 years

168

Employees

Kiniksa Pharmaceuticals Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $5.87 billion, with shareholders equity totaling $654.15 million.

The company employs approximately 168 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Kiniksa Pharmaceuticals Ltd. reported $840.85 million in revenue, generating net income of $80.66 million.

Key financial metrics include a P/E ratio of 72.72, a price-to-book (P/B) ratio of 8.97, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker KNSA.

Market cap

$5.87 billion

Net worth

$654.15 million

$654,149,000.00

Assets

$896.11 million

$896,110,000.00

Total Shares Outstanding

77.58 million

77,577,000

Average Daily Trading Volume

$607.06 Thousand

$607,059.98

Sector

Health Care

Industry

Biotechnology

KNSA

KNSA revenue and profits

Financial Results KNSA

DRAG THE FRAME TO SEE MORE DATA

KNSA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$888.29 20,83% (12M)

P/E

22.96

0.38%

ROE

-118.84%

P/BV

-27.29

CAH - Cardinal Health

$226.17 47,96% (12M)

P/E

30.94

0.91%

ROE

-62.92%

P/BV

-19.47

ABBV - AbbVie

$259.97 14,69% (12M)

P/E

72.88

2.63%

ROE

-106.44%

P/BV

-77.57

MRK - Merck & Co.

$143.18 65,85% (12M)

P/E

110.80

2.36%

ROE

7.56%

P/BV

8.37

AZN - AstraZeneca

$156.59 --6,84% (12M)

P/E

18.71

2.06%

ROE

25.77%

P/BV

4.82

PFE - Pfizer

$27.48 7,47% (12M)

P/E

36.14

6.26%

ROE

5.07%

P/BV

1.83

BMY - Bristol-Myers Squibb

$60.33 39,02% (12M)

P/E

13.14

4.20%

ROE

41.59%

P/BV

5.46

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$888.29 20,83% (12 M)

P/L

22.96

0.38%

ROE

-118.84%

P/VP

-27.29

CAH - Cardinal Health

$226.17 47,96% (12 M)

P/L

30.94

0.91%

ROE

-62.92%

P/VP

-19.47

ABBV - AbbVie

$259.97 14,69% (12 M)

P/L

72.88

2.63%

ROE

-106.44%

P/VP

-77.57

MRK - Merck & Co.

$143.18 65,85% (12 M)

P/L

110.80

2.36%

ROE

7.56%

P/VP

8.37

AZN - AstraZeneca

$156.59 --6,84% (12 M)

P/L

18.71

2.06%

ROE

25.77%

P/VP

4.82

PFE - Pfizer

$27.48 7,47% (12 M)

P/L

36.14

6.26%

ROE

5.07%

P/VP

1.83

BMY - Bristol-Myers Squibb

$60.33 39,02% (12 M)

P/L

13.14

4.20%

ROE

41.59%

P/VP

5.46

Frequently Asked Questions

What is the price of Kiniksa Pharmaceuticals (KNSA) today?

The current price of Kiniksa Pharmaceuticals (KNSA) is $75.61. The stock began the year trading around $41.25 and is currently priced at $75.61. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Kiniksa Pharmaceuticals (KNSA) pay dividends?

Kiniksa Pharmaceuticals (KNSA) did not pay dividends over the past year.

Is Kiniksa Pharmaceuticals (KNSA) a good investment?

Kiniksa Pharmaceuticals (KNSA) is currently trading at $75.61 with a P/E ratio of 72.72. This represents a 3,719% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 96.44%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Kiniksa Pharmaceuticals (KNSA) stock?

You can buy Kiniksa Pharmaceuticals (KNSA) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol KNSA and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Kiniksa Pharmaceuticals (KNSA) yield today?

Over the past month, Kiniksa Pharmaceuticals (KNSA) has returned -4.57% — 96.44% over the past year, and 593.03% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Kiniksa Pharmaceuticals (KNSA) today at the current price of $75.61 your total investment would be $7,561.00.

Based on historical performance, the investment would have grown to approximately:

$14,852.83 after 1 year
$52,400.00 after 5 years
$7,561.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

KNSA

Kiniksa Pharmaceuticals Ltd.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment KNSA

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING KNSA WITH OTHER STOCK

ABOUT Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Ltd.

United States

11 years

2018

168

PROFIT X PRICE KNSA

Financial Results KNSA

KNSA cash flow

Asset, Revenue and Profit Growth - KNSA

KNSA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions